Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
Please note that the ANZCTR website will be unavailable from 9am until 12:30pm (AEDT) on Tuesday 17th November for website maintenance.
Please be sure to log out of the system in order to avoid any loss of data. Thank you and apologies for any inconvenience caused.
A database of clinical trials and their results from Australia, New Zealand, and other countries.
account_circle
Log in
to register or update your trial
search
Search for trials
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial registered on ANZCTR
Registration number
ACTRN12624001138572
Ethics application status
Approved
Date submitted
26/07/2024
Date registered
20/09/2024
Date last updated
18/11/2025
Date data sharing statement initially provided
20/09/2024
Type of registration
Prospectively registered
Titles & IDs
Public title
A Phase 1/2a, First-In-Human, Single and Multiple Ascending Dose Escalation and Dose Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Clinical Efficacy of Intralesional FLD-103 in Subjects with Basal Cell Carcinoma (BCC)
Query!
Scientific title
A Phase 1/2a, First-In-Human, Single and Multiple Ascending Dose Escalation and Dose Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Clinical Efficacy of Intralesional FLD-103 in Subjects with Basal Cell Carcinoma (BCC)
Query!
Additional trial identifiers [1]
312079
0
P01-CLIN01
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
Query!
Related trial records
Query!
Health condition
Health condition(s) studied:
Basal Cell Carcinoma
333704
0
Query!
Condition category
Condition code
Cancer
330385
330385
0
0
Query!
Non melanoma skin cancer
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of the intervention or exposure
This is a multi-centre, phase 1, open-label, single ascending dose (SAD) and multiple ascending dose (MAD) study, to determine the safety, tolerability, pharmacokinetics, preliminary efficacy, and maximum tolerated dose (MTD) of intralesional FLD-103 when administered to subjects with Basal Cell Carcinoma (BCC). FLD-103 will be injected directly in the central areas of the tumour.
This Phase of the study is planned to enrol at least 18 subjects with BCC. Each subject will receive either a single dose of FLD-103 or multiple doses of FLD-103 once weekly for four (4) weeks. FLD-103 is comprised of two (2) components, FSD147L and PMO-Gli1 formulated as an intralesional injection.
FLD-103 is provided as a ready-to-use formulation in single-use sterile 1.0 mL vials filled with 0.95 mL of IP solution. The volume of FLD-103 to be injected throughout the study will be determined by the initial size of the lesion, at Baseline.
In Part 1, participants will be assigned to receive one of three (3) initial dose levels (DL). Either 0.5 mg/ml (cohort 1SAD and 1MAD), 1.0 mg/mL (cohort 2SAD and 2MAD) or 3.0 mg/mL (cohort 3SAD and 3MAD) of FLD-103 in an open-label fashion.
At least six (6) single and multiple dose Cohorts of 3 + 3 eligible subjects will be studied in Part 1 (Phase 1) initially, as required. However, based on the SRC review of each individual Cohort, and preliminary efficacy results, the total number of Cohorts and the doses administered may be revised.
Participants will be assigned to either the SAD or MAD based on the timing of their screening visit.
Initially three subjects are planned to be sequentially enrolled into each Cohort according to a detailed Dose Level Guide:
- At least three (3) Cohorts will be administered a single dose of FLD-103, and named accordingly (1s, 2s, 3s, etc), and
- At least three (3) Cohorts will be administered FLD-103 once weekly for four (4) weeks and named accordingly (1m, 2m, 3m, etc).
A sentinel subject will be required in each SAD Cohort.
A review of the sentinel subject will be made by the Principal Investigator (PI) and Medical Monitor (MM) 48 hours after their dosing. If no safety concerns are reported, the remaining two (2) subjects in the Cohort will be dosed a minimum of 24 hours after the completion of the safety evaluation of the sentinel subject in that Cohort (along with commencement of dosing for the multiple dose Cohort at the DL below, if applicable).
Once all subjects of a Cohort have been dosed, all available safety and tolerability data, from evaluable subjects to Day 8 for the single dose Cohorts or Day 29 for the multiple dose Cohorts, will be reviewed by the Safety Review Committee (SRC). The SRC will consist of the Lead PI, the Local MM, a Sponsor Delegate and an independent clinician with relevant therapeutic expertise. According to the occurrence of Dose Limiting Toxicity (DLT) within the initial three (3) subjects within a Cohort, the SRC will make a recommendation: 1) escalate to the next dose level (DL) (and initiate concurrent multiple dosing at the current DL, if applicable), 2) enrol three (3) additional subjects at the current dose or 3) the current dose is not tolerated, meaning that the Maximum Tolerable Dose (MTD) has been exceeded and no further escalation is to occur for that dose regimen (SAD or MAD). The SRC will then have the option to declare the previous dose as the MTD or recommend enrolling three (3) additional subjects to the previous DL Cohort. In the instance that a DL in the MAD cohort is not tolerated, no further escalating in the MAD will occur but further escalation in the SAD cohorts may occur if the SRC recommends it.
It is anticipated that initially three (3) dose concentrations of FLD-103 (DL1: 0.50 mg/mL FSD147L / 0.63 mg/mL PMO-Gli1; DL2: 1.00 mg/mL FSD147L / 1.26 mg/mL PMO-Gli1 and DL3: 3.00 mg/mL FSD147L / 3.77 mg/mL PMO-Gli1) will be administered in the study. However, based on the SRC review of each individual Cohort, and preliminary efficacy results, the total number of Cohorts and the doses administered may be revised.
Query!
Intervention code [1]
328528
0
Treatment: Drugs
Query!
Description of the comparator or control
No control group
Query!
Control group
Uncontrolled
Query!
Outcomes
Primary outcome [1]
338157
0
SAD Study - To evaluate the safety and tolerability of ascending single intralesional doses of FLD-103 administered to subjects with BCC
Query!
Assessment method [1]
338157
0
Safety endpoints include: - Frequency and severity of Treatment Emergent Adverse events (TEAEs) - Local Skin Response (LSR) and other potential localised responses - Changes from Baseline in Vital signs - Changes in Baseline 12 lead ECG - Changes in Baseline physical examination, - Changes in Baseline laboratory assessments: Clinical chemistry, Hematology, Coagulation, Routine urinalysis - Development of anti-FLD-103 antibodies All measures will be assessed as a composite primary outcome 'To evaluate the safety and tolerability of ascending single intralesional doses of FLD-103 administered to subjects with BCC'.
Query!
Timepoint [1]
338157
0
Adverse events - The Investigator will make an assessment of severity for each AE and SAE reported during the study. AEs will be scored in accordance with the Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0. The severity of each AE and SAE will be assessed continuously as they are reported or observed and reviewed daily up until end of study (EOS) visit at Day 46. Local Skin Response (LSR) and other potential localised responses will be performed pre-dose on Day 1, and post-dose on Day 1, Day 8 and Day 36. Vital signs - Measured at screening, pre-dose on Day 1, and post-dose on Day 1, Day 2, Day 3, Day 8, Day 15, Day 29 and Day 36. Vital signs consist of blood pressure and heart rate which will be measured using a sphygmomanometer, respiratory rate by manual breath count and temperature by thermometer. Electrocardiogram (ECG) - 12-lead ECG recordings will be obtained in triplicate at screening, pre-dose on Day 1, and post-dose on Day 1, Day 2, Day 3, and Day 36. Clinical laboratory evaluations (clinical chemistry, hematology, coagulation, routine urinalysis - blood and urine samples will be collected at screening and pre-dose at Day 1, Day 2, Day 3, Day 8, and Day 36. Development of anti-FLD-103 antibodies - A blood sample will be collected pre-dose on Day 1, Day 8 and Day 29.
Query!
Primary outcome [2]
338203
0
MAD Study - To evaluate the safety and tolerability of ascending multiple intralesional doses of FLD-103 administered to subjects with BCC
Query!
Assessment method [2]
338203
0
Safety endpoints include: - Frequency and severity of Treatment Emergent Adverse events (TEAEs) - Local Skin Response (LSR) and other potential localised responses - Changes from Baseline in Vital signs - Changes in Baseline 12 lead ECG - Changes in Baseline physical examination, - Changes in Baseline laboratory assessments: Clinical chemistry, Hematology, Coagulation, Routine urinalysis - Development of anti-FLD-103 antibodies All measures will be assessed as a composite primary outcome 'To evaluate the safety and tolerability of ascending single intralesional doses of FLD-103 administered to subjects with BCC'
Query!
Timepoint [2]
338203
0
Adverse events - The Investigator will make an assessment of severity for each AE and SAE reported during the study. AEs will be scored in accordance with the Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0. The severity of each AE and SAE will be assessed continuously as they are reported or observed and reviewed daily up until end of study (EOS) visit at Day 67. Local Skin Response (LSR) and other potential localised responses - Assessed pre-dose on Day 1, and post-dose at Day 29 and Day 57. Vital signs - Measured at screening, pre-dose on Day 1, Day 8, Day 16 and Day 22 and post-dose on Day 1, Day 2, Day 3 (if needed), Day 9, Day 16, Day 23, Day 29, Day 36 , Day 43 (if needed), Day 50 (if needed) and Day 57. Vital signs consist of blood pressure and heart rate which will be measured using a sphygmomanometer, respiratory rate by manual breath count and temperature by thermometer. Electrocardiogram (ECG) - 12-lead ECG recordings will be obtained in triplicate at screening, pre-dose at Day 1, Day 8, Day 15 and Day 22 and post-dose at Day 2 and Day 57. Clinical laboratory evaluations (clinical chemistry, hematology, coagulation, routine urinalysis - Blood and urine samples will be collected at screening and pre-dose at Day 1, Day 8, Day 15 and Day 22 and post-dose at Day 2, Day 29 and Day 57. Development of anti-FLD-103 antibodies - A blood sample will be collected pre-dose on Day 1 and Day 8 and post-dose on Day 29.
Query!
Secondary outcome [1]
434750
0
SAD Study - To evaluate the pharmacokinetics (PK) of FLD-103 following single intralesional doses administered to subjects with BCC
Query!
Assessment method [1]
434750
0
Plasma PK endpoints for SAD, including: - Maximum observed concentration (Cmax) - Time to Cmax (tmax) - Area under the concentration-time curve from 0 to time of last quantifiable concentration (AUClast) - Area under the concentration-time curve from 0 to infinity (AUCinf) - Area under the concentration-time curve from 0 to a specified time point post-dose (AUC0-t), such as t = 24h - Apparent terminal elimination half-life (t1/2) if data permit - Terminal elimination rate constant (Kel)
Query!
Timepoint [1]
434750
0
Blood plasma samples will be collected via venepuncture pre-dose on Day 1 and post-dose on Day 1, Day 2, Day 3 and Day 8.
Query!
Secondary outcome [2]
434956
0
MAD Study - To evaluate the pharmacokinetics (PK) of FLD-103 following multiple intralesional doses administered to subjects with nBCC
Query!
Assessment method [2]
434956
0
Plasma PK endpoint for MAD, including: - Pre-dose plasma FLD-103 concentration (trough level)
Query!
Timepoint [2]
434956
0
Blood plasma samples will be collected via venepuncture pre-dose on Day 1, Day 8, Day 15 and Day 22 and post-dose on Day 29 and Day 36
Query!
Secondary outcome [3]
434957
0
SAD Study - To make a preliminary assessment of tumour response to FLD-103
Query!
Assessment method [3]
434957
0
Overall response rate (ORR) will be assessed independently. The change in the target lesion diameter, as measured by callipers, will be used to categorise patients as either responders or non-responders for the evaluation of ORR, in accordance with the target lesion response component of modified RECIST v1.1
Query!
Timepoint [3]
434957
0
Lesion assessment and measurement will be performed at Screening, pre-dose on day 1, then post-dose on day 8, day 15, day 29 and day 36.
Query!
Secondary outcome [4]
438955
0
MAD Study - To make a preliminary assessment of tumour response to FLD-103
Query!
Assessment method [4]
438955
0
Overall response rate (ORR) will be assessed independently. The change in the target lesion diameter, as measured by callipers, will be used to categorise patients as either responders or non-responders for the evaluation of ORR, in accordance with the target lesion response component of modified RECIST v1.1
Query!
Timepoint [4]
438955
0
Lesion assessment and measurement will be performed at Screening, pre-dose on day 1, day 8, day 15, day 22, then post dose on day 29, day 36 and day 57.
Query!
Secondary outcome [5]
439620
0
SAD Study - To make a preliminary assessment of tumour response to FLD-103
Query!
Assessment method [5]
439620
0
Complete response rate (CRR) will be assessed independently. The change in the target lesion diameter, as measured by callipers, will be used to categorise patients as either responders or non-responders for the evaluation of CRR, in accordance with the target lesion response component of modified RECIST v1.1
Query!
Timepoint [5]
439620
0
Lesion assessment and measurement will be performed at Screening, pre-dose on day 1, then post-dose on day 8, day 15, day 29 and day 36.
Query!
Secondary outcome [6]
439621
0
MAD Study - To make a preliminary assessment of tumour response to FLD-103
Query!
Assessment method [6]
439621
0
Complete response rate (CRR) will be assessed independently. The change in the target lesion diameter, as measured by callipers, will be used to categorise patients as either responders or non-responders for the evaluation of CRR, in accordance with the target lesion response component of modified RECIST v1.1
Query!
Timepoint [6]
439621
0
Lesion assessment and measurement will be performed at Screening, pre-dose on day 1, day 8, day 15, day 22, then post dose on day 29, day 36, day 43. day 50 and day 57.
Query!
Secondary outcome [7]
439622
0
SAD Study - To make a preliminary assessment of tumour response to FLD-103
Query!
Assessment method [7]
439622
0
Percentage change from baseline in target lesion diameter will be assessed independently. The change in the target lesion diameter, as measured by callipers, will be used for the evaluation of percentage change from baseline in target lesion diameter.
Query!
Timepoint [7]
439622
0
Lesion assessment and measurement will be performed at Screening, pre-dose on day 1, then post-dose on day 8, day 15, day 29 and day 36.
Query!
Secondary outcome [8]
439623
0
MAD study - To make a preliminary assessment of tumour response to FLD-103
Query!
Assessment method [8]
439623
0
Percentage change from baseline in target lesion diameter will be assessed independently. The change in the target lesion diameter, as measured by callipers, will be used for the evaluation of percentage change from baseline in target lesion diameter.
Query!
Timepoint [8]
439623
0
Lesion assessment and measurement will be performed at Screening, pre-dose on day 1, day 8, day 15, day 22, then post dose on day 29, day 36 and day 57.
Query!
Secondary outcome [9]
454848
0
SAD Study - To make a preliminary assessment of tumour response to FLD-103
Query!
Assessment method [9]
454848
0
Rate of histological clearance of the nBCC will be assessed at a central laboratory. Histological clearance of the nBCC will be determined based on the histology of the excised tissue. Patients with clearance of the nBCC, as determined by the histological analysis of the excised tissue, will be classified as responders for the histological clearance endpoint, and all other patients will be classified as non-responders.
Query!
Timepoint [9]
454848
0
Rate of histological clearance of the nBCC will be performed on the tissue excised at the day 36 visit.
Query!
Secondary outcome [10]
454849
0
MAD Study - To make a preliminary assessment of tumour response to FLD-103
Query!
Assessment method [10]
454849
0
Rate of histological clearance of the nBCC will be assessed at a central laboratory. Histological clearance of the nBCC will be determined based on the histology of the excised tissue. Patients with clearance of the nBCC, as determined by the histological analysis of the excised tissue, will be classified as responders for the histological clearance endpoint, and all other patients will be classified as non-responders.
Query!
Timepoint [10]
454849
0
Rate of histological clearance of the nBCC will be performed on the tissue excised at the day 57 visit.
Query!
Eligibility
Key inclusion criteria
1. At least 18 years of age and up to 85 years of age, inclusive, at the time of signing the informed consent.
2. Capable of giving written informed consent, which includes compliance with the requirements and restrictions listed in the consent form and is willing and able to return for all study visits and comply with all protocol requirements and procedures.
3. At Screening, the subject must have at least a single histologically confirmed nBCC suitable for treatment and final excision by the Investigator.
4. A nBCC previously biopsied outside the study as part of standard clinical practice may be re-biopsied within the study, provided that less than approximately 25 percent of the area of the nodular lesion is removed as a result of the second biopsy.
5. If no previous biopsy is available, target nBCC must be appropriate for a full thickness 2 mm punch biopsy (for lesions from 5 mm up to less than 10 mm diameter) or preferrably a 3 mm punch biopsy (for lesions from 10 mm to less than 20 mm diameter), taken approximately halfway from the centre or outer border of each target nBCC, within 14 to 42 days prior to Day 1 for histological confirmation at Baseline. The biopsy(ies) must remove less than approximately 25 percent of the area of the nBCC.
6. Target BCC must, in the assessment of the Investigator, be appropriate for FLD-103 intralesional treatment over the anticipated duration of the study.
7. Female volunteers, must:
a. Be of non-child-bearing potential i.e., surgically sterilised (hysterectomy, bilateral salpingectomy, bilateral oophorectomy) at least 6 weeks before the Screening visit, or
b. Be postmenopausal (where postmenopausal is defined as no menses for 12 months without an alternative medical cause and follicle-stimulating hormone (FSH) level consistent with postmenopausal status, per local laboratory guidelines).
8. Male volunteers, must:
a. Agree not to donate sperm from signing the consent form until at least 90 days after the last dose of study drug.
b. If engaging in sexual intercourse with a female partner who could become pregnant, agree to use adequate contraception (defined as use of a condom combined with use of a highly effective method of contraception from signing the consent form until at least 90 days after the last dose of study drug.
c. If engaging in sexual intercourse with a female partner who is not of childbearing potential or a same-sex partner, agree to use a condom from signing the consent form until at least 90 days after the last dose of study drug.
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
85
Years
Query!
Query!
Sex
Both males and females
Query!
Healthy volunteers
No
Query!
Key exclusion criteria
1. Women of childbearing potential or who are breastfeeding.
2. History of sensitivity to any of the components in the Investigational Product (IP) formulation.
3. Target lesion in high-risk anatomic location (e.g. ocular/peri-ocular, nose/perinasal, ears, lips/perioral, scalp, fingers/hands).
4. Target lesion requiring immediate surgical removal.
5. Clinically confirmed concurrent diagnosis of locally advanced or metastatic BCC.
6. Use of known inhibitors of the HH signalling pathway (including but not limited to vismodegib, sonidegib, itraconazole) within four (4) weeks of Screening.
7. Use of topical or intralesional treatment within 5 cm of the target BCC (e.g. 5-FU, imiquimod, topical corticosteroids, retinoids) within the specified period
8. Has received or is expected to receive phototherapy, including treatment with psoralen plus UVA or UVB therapy, within 4 weeks of the Screening visit or during the study.
9. Use of another Investigational Product (IP) within thirty (30) days or five (5) halflives or twice the duration of biological effect (whichever is the longest) preceding the first dose of FLD-103.
10. Subjects who have received radiation therapy to the target lesion and surrounding area (within 5 cm). Radiation to an unrelated body area is acceptable if done at least 30 days prior to Screening.
11. A history of, or current hepatic disease, or known hepatic or biliary abnormalities that in the opinion of the Investigator would preclude the subject from participation in the study.
12. Moderate to severe renal impairment, including subjects on chronic renal dialysis and subjects with a history of nephrectomy or kidney transplant (regardless of renal function)
13. History of alcohol or drug abuse within the past 180 days, or a positive pre-study drug screen (unless the positive result is consistent with the use of a prescribed medication (e.g., codeine, benzodiazepines) or cannabinoids, as documented by the Investigator), or any current mental health condition (including, but not limited to, psychiatric disorder or dementia), that in the opinion of the Investigator, may interfere with study compliance, affect informed consent capacity, or impact the subject’s ability to follow the protocol and attend study visits.
14. History or current evidence of any condition, laboratory abnormality or situation which, in the Investigator’s opinion, may put the subject’s safety at significant risk, confound the study results, interfere with the evaluation of the target lesion/treatment area or interfere with the subject’s participation in the study, (for example, but not limited to, other clinically active or uncontrolled skin disorders or tattoos that would interfere with evaluation of the area surrounding the target BCC, uncontrolled systemic disease such as metabolic dysfunction, clinically significant 12-lead ECG abnormalities, and any other physical examination findings, or abnormal clinical laboratory findings).
15. Diagnosis of Xeroderma Pigmentosum or any other skin disorder that is associated with an abnormal rate of development of skin cancers or which may interfere with administration of the treatment and/or assessment of the target nBCC.
16. History of any malignancy within the past five (5) years or has a known malignancy that is progressing or requires active treatment excluding BCC or non-metastatic squamous cell carcinoma, successfully treated melanoma stage 0 or 1, or in situ cervical cancer or prostate cancer, Gleason score 6 or lower.
17. Immunocompromised (e.g. active Hepatitis A or B infection, current Hepatitis C infection, HIV infection) or receiving or expected to receive an immunomodulating agent (including immunosuppressive agents, cytotoxic drugs, biological agents, immunoglobulins, interferon or other immune or cytokine-based therapies. Use of oral corticosteroids at doses higher than physiological replacement doses (used in e.g. adrenal or pituitary insufficiency) is an exclusion criterion.
18. Heart rate less than 40 or greater than 100 bpm; systolic blood pressure (SBP) greater than 140 mmHg; diastolic blood pressure (DBP) greater than 90 mmHg measured in up to three (3) separate intervals after resting for five (5) minutes in a supine or semi-recumbent position. Subjects with a history of hypertension are eligible if their condition is controlled and they have been on a stable dose of antihypertensive medications for at least four (4) weeks prior to Screening.
19. Prolonged mean QTcF (QT interval corrected for heart rate using Fridericia’s formula) greater than 450 ms for male subjects or greater than 470 ms for female subjects, or a shortened QTcF less than 300 ms or a family history of prolonged QT syndrome, at Screening.
20. Employee of the Investigator or study centre, with direct or indirect involvement in the proposed study or other studies under the direction of that Investigator or study centre, as well as family members of the employees or the Investigator.
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Non-randomised trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Open (masking not used)
Query!
Who is / are masked / blinded?
Query!
Query!
Query!
Query!
Intervention assignment
Single group
Query!
Other design features
Query!
Phase
Phase 1
Query!
Type of endpoint/s
Safety/efficacy
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Recruiting
Query!
Date of first participant enrolment
Anticipated
21/10/2024
Query!
Actual
30/10/2024
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
Query!
Sample size
Target
18
Query!
Accrual to date
13
Query!
Final
Query!
Recruitment in Australia
Recruitment state(s)
ACT,NSW,QLD,VIC
Query!
Funding & Sponsors
Funding source category [1]
316438
0
Commercial sector/Industry
Query!
Name [1]
316438
0
Feldan Therapeutics
Query!
Address [1]
316438
0
Query!
Country [1]
316438
0
Canada
Query!
Primary sponsor type
Commercial sector/Industry
Query!
Name
Feldan Therapeutics
Query!
Address
Query!
Country
Canada
Query!
Secondary sponsor category [1]
318607
0
Commercial sector/Industry
Query!
Name [1]
318607
0
Avance Clinical
Query!
Address [1]
318607
0
Query!
Country [1]
318607
0
Australia
Query!
Ethics approval
Ethics application status
Approved
Query!
Ethics committee name [1]
315230
0
Bellberry Human Research Ethics Committee
Query!
Ethics committee address [1]
315230
0
https://www.bellberry.com.au
Query!
Ethics committee country [1]
315230
0
Australia
Query!
Date submitted for ethics approval [1]
315230
0
19/06/2024
Query!
Approval date [1]
315230
0
07/08/2024
Query!
Ethics approval number [1]
315230
0
Query!
Ethics committee name [2]
319133
0
Metro South Human Research Ethics Committee
Query!
Ethics committee address [2]
319133
0
https://www.metrosouth.health.qld.gov.au/research/research-ethics-and-governance/human-research-ethics-committee
Query!
Ethics committee country [2]
319133
0
Australia
Query!
Date submitted for ethics approval [2]
319133
0
11/03/2025
Query!
Approval date [2]
319133
0
08/05/2025
Query!
Ethics approval number [2]
319133
0
Query!
Summary
Brief summary
This study aims to determine the safety, tolerability, pharmacokinetics, preliminary efficacy, and maximum tolerated dose (MTD) of intralesional FLD-103 when administered to subjects with Basal Cell Carcinoma. Who is it for? You may be eligible to join this study if you are a male or female aged 18 to 85 years old and have at least a single histologically confirmed nBCC suitable for treatment. A nBCC previously biopsied outside the study as part of standard clinical practice may be re-biopsied within the study, provided that approximately less than 25 percent of the area of the nodular lesion is removed as a result of the second biopsy. Study details All participants who meet the eligibility criteria in this study will receive either a single dose of FLD-103 or multiple doses of FLD-103 once weekly for four (4) weeks. FLD-103 is comprised of two (2) components, FSD147L and PMO-Gli1 formulated as an intralesional injection. During and after completion of the treatment participants will be assessed for safety and tolerability of FLD-103, plasma PK and tumor response. It is hoped the research in the Dose Escalation Phase (Part 1) will determine the maximum dose of FLD-103 that can be administered safely without causing severe reactions. Once Part 1 is completed, Part 2 will then evaluate one or more dose level(s) deemed to be safe and well tolerated, based on the data from the Part 1 of the study. A sentinel subject will be required in each Single Ascending Dose Cohort. . Once all subjects of a Cohort have been dosed, all available safety and tolerability data, from evaluable subjects will be reviewed. Updated due to protocol amendment. Update made after enrollment of 13 participants
Query!
Trial website
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
134062
0
Dr Juliana Junger
Query!
Address
134062
0
NovaTrials, Suite 301, 99 Pacific Highway, Charlestown NSW 2290, Australia
Query!
Country
134062
0
Australia
Query!
Phone
134062
0
+61 2 4089 3744
Query!
Fax
134062
0
Query!
Email
134062
0
[email protected]
Query!
Contact person for public queries
Name
134063
0
Catherine Lippe
Query!
Address
134063
0
Feldan Therapeutics, 2666 Boul. du Parc-Technologique, Suite 290, Quebec QC G1P 4S6 Canada
Query!
Country
134063
0
Canada
Query!
Phone
134063
0
+1 418 872 7277
Query!
Fax
134063
0
Query!
Email
134063
0
[email protected]
Query!
Contact person for scientific queries
Name
134064
0
Catherine Lippe
Query!
Address
134064
0
Feldan Therapeutics, 2666 Boul. du Parc-Technologique, Suite 290, Quebec QC G1P 4S6 Canada
Query!
Country
134064
0
Canada
Query!
Phone
134064
0
+1 418 872 7277
Query!
Fax
134064
0
Query!
Email
134064
0
[email protected]
Query!
Data sharing statement
Will the study consider sharing individual participant data?
No
What supporting documents are/will be available?
No Supporting Document Provided
Results publications and other study-related documents
Documents added manually
No documents have been uploaded by study researchers.
Documents added automatically
No additional documents have been identified.
Download to PDF